Alzheimer's Disease is a neurodegenerative disease where the build-up of the proteins amyloid and tau damage the nerve cells in the brain. A progressive disorder, Alzheimer’s develops over time with symptoms increasing in severity.
Between 60–80% of dementia cases are caused by Alzheimer's disease. Rapid diagnosis is important, as treatment early in the course of AD helps maintain cognitive and functional performance and delay the emergence of distressing behavioural and psychological symptoms, such as depression, anxiety and apathy.
Cholinesterase inhibitors can be used alone or in combination to manage the behavioural and psychological symptoms of Alzheimer's disease. However current treatments do not cure Alzheimer's disease and functional and cognitive decline are inevitable.
To find out more about Alzheimer's Disease visit our dedicated Learning Zone, which contains expert-led information on diagnosing behavioural and psychological symptoms, and the treatment options available.
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
<strong>Objectives: </strong>To define a practice guideline for biological treatment of dementia and to make transparent the development of the guideline connecting the original data with the resulting recommendations.
Related news and insights
Tauvid a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD).
Eli Lilly and Company announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild dementia (MILD), and caring for someone with Alzheimer's disease (AD).
Axsome Therapeutics, Inc. announced that AXS 05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary endpoint in the ADVANCE-1 Phase II/III trial and rapidly, substantially, and significantly improved agitation in patients with Alzheimer’s disease as compared to placebo.